PRZOOM - /newswire/ -
Albuquerque, NM, United States, 2010/02/10 - John Cousins, president of cancer diagnostics company Biomoda, Inc., has been elected to the Board of Directors of the New Mexico Biotechnology and Biomedical Association (NMBio) (OTC BB: BMOD).
“I know firsthand how receptive New Mexico is to the bioscience industry,” Cousins said. “NMBio plays a critical role in promoting our industry and our region by providing a platform for interaction between the science side and the business side of biotech.”
NMBio was established to provide a forum for information exchange in the life sciences, develop initiatives to enhance small business success, provide education and outreach, help establish collaborations, and publicize the New Mexico bioscience industry. NMBio is an affiliate of the national Biotechnology Industry Organization.
As a member of the NMBio Board of Directors, Cousins joins a volunteer group of scientists, academics and other professionals dedicated to the advancement of bioscience in New Mexico and the promotion of New Mexico’s capabilities internationally. During his two-year term, Cousins will be involved in NMBio-sponsored programs and events, policy development and a variety of committee assignments.
“Biomoda has benefited from our affiliation with NMBio and I look forward to building the biotech community in New Mexico by helping other companies in the bioscience sector succeed,” Cousins said.
Biomoda’s initial product is a diagnostic assay for the detection of early-stage lung cancer. Currently in Phase II clinical trials, the CyPath® assay is a porphyrin-based compound that preferentially binds to cancer cells and causes them to fluoresce red under ultraviolet light. CyPath® is for investigational use only pending approval by the U.S. Food and Drug Administration (FDA).
Biomoda (OTC BB: BMOD) (biomoda.com) is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer. Current research and development operations, laboratory functions for both microscopy and assay formulation, and administrative offices are located in Albuquerque, NM.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on estimates, projections, beliefs and assumptions of Biomoda management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. Forward-looking statements are made as of the date of this press release and are subject to change without notice.